Loading...
Symbols:
Loading...
Symbols:
PDL BioPharma Inc. (PDLI)
|
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: |
Articles on PDL BioPharma Inc. (PDLI)
35 articles
Filter by:
Latest Articles Most commented on articlesMost frequent authors on PDLI
- Lon Juricic(16)
- SA Editor Miriam Metzinger(5)
- Travis Johnson(4)
- Bespoke Investment Group(3)
- Andrew Wilkinson(2)
Most popular authors
(tracked in watchlists)
- Bespoke Investment Group(575)
- Andrew Wilkinson(334)
- Mebane Faber(147)
- Davy Bui(124)
- SA Editor Miriam Metzinger(120)
Most commented on authors
- Davy Bui(7)
- Mebane Faber(6)
- Lon Juricic(4)
- Travis Johnson(3)
- SA Editor Miriam Metzinger(1)
- 15 Value Hedge Funds - Portfolio Update
- Bristol-Myers Ponies Up for Elotuzumab
- Seth Klarman, Meryl Witmer and Marty Whitman - Q2 2008 Portfolio Moves
- Top Holdings of the Top Hedge Fund Earners Last Year
- Last Week's Winners and Losers
- Friday's Options Report: C, WM, CCJ, LNG, PDLI, LTD
- Healthcare Stocks Have Been Anything but Defensive
- Wednesday's Options Report: TIBX, NUAN, DFS, XLF, PDLI, ORCL, XLK
- Highland Capital Wants PDL BioPharma To Hire New Advisor
- Loeb Says Goodbye to PDL BioPharma
- PDL BioPharma: Loeb's Third Point Lowers Stake to 5.1%
- PDL BioPharma Yields To Activists, Stock Jumps
- Highland Capital Joins Loeb In Calling For a Sale of PDL BioPharma
- Activist Target PDL BioPharma Under Fire; Loeb And Others Raise the Heat
- PDL Biopharma: Shorting Above $19 is a Safe Bet
- PDL BioPharma: Loeb Finally Gets CEO McDade's Head
- Loeb's Third Point Issues Latest 13F: Summary of Holdings
- PDL BioPharma: Loeb's Third Point Reiterates Demand to Terminate CEO
- PDL BioPharma: Is CEO McDade On the Way Out?
- PDL BioPharma: Loeb's Third Point Wants Chairman Dismissed
- Four Cheap Biotech Stock Picks: Amgen, Aspreva, Exelixis, PDL Biopharma
- PDL BioPharma: Co-Founder Queen Supports Third Point's Proposals
- PDL BioPharma: Loeb Reiterates Demand For CEO McDade's Resignation
- Hedge Fund Increases Heat On PDL BioPharma CEO
- PDL BioPharma: Loeb's Third Point Wants CEO McDade Out
- What Does Third Point See in PDL Biopharma?
- PDL BioPharma: Third Point Raises Stake, Requests Four Seats on Board
- Biotech Day in Review: Schering-Plough Buys Organon for $14.4 Billion
- Indirect Investing Opportunities in Different Industries
- PDL BioPharma: Third Point Raises Stake, Urges Company to Cut Costs
- Genentech 4th Quarter Report Leads Biotech Rally
- PDL Biopharma: Troubled Summer, But Holding On
- Biotech Portfolio Overview: PDL Biopharm Still Cheap, CV Therapeutics Still Falling
-
Analyst Upgrades & Downgrades for Monday July 24, 2006
on Jul 24, 2006
- Buying PDL BioPharma On The Dip (PDLI)
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »